Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program

blonca9
Jun 26, 2024
1 min read

Paul Bolno highlights biomarker and safety data in Huntington's, the potential regulatory path ahead, and what to watch throughout the rest of the year from Wave's DMD, AATD, and weight loss programs.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Wave Life Sciences' CEO Paul Bolno discusses Phase 1b/2a data from the company's allele-selective Huntington's program

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight